Literature DB >> 3558097

Evaluation of some prognostic factors for advanced multicentric lymphosarcoma in the dog: 147 cases (1978-1981).

E G MacEwen, A A Hayes, R E Matus, I Kurzman.   

Abstract

A total of 147 dogs treated with a combination of chemotherapy procedure (vincristine, L-asparaginase, cyclophosphamide, and methotrexate) were evaluated for response to therapy and the influence of age, sex, clinical stage, and body weight to duration of response. Complete response was achieved in 113 dogs (77%), partial response in 26 dogs (17.7%), and no response in 8 dogs (5.4%). The median survival time for the dogs with complete and partial responses was 265 days. An analysis of factors associated with prognosis revealed that age, clinical stage, and body weight were not associated with response to therapy, whereas sex was. Females had a significantly prolonged remission and survival time (P = 0.0001).

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3558097

Source DB:  PubMed          Journal:  J Am Vet Med Assoc        ISSN： 0003-1488            Impact factor:   1.936


  6 in total

1.  Clonality and phenotyping of canine lymphomas before chemotherapy and during remission using polymerase chain reaction (PCR) on lymph node cytologic smears and peripheral blood.

Authors:  Dilini N Thilakaratne; Monique N Mayer; Valerie S MacDonald; Marion L Jackson; Brenda R Trask; Beverly A Kidney
Journal:  Can Vet J       Date:  2010-01       Impact factor: 1.008

Review 2.  Spontaneous tumors in dogs and cats: models for the study of cancer biology and treatment.

Authors:  E G MacEwen
Journal:  Cancer Metastasis Rev       Date:  1990-09       Impact factor: 9.264

3.  Factors associated with long-term survival in dogs undergoing liver lobectomy as treatment for liver tumors.

Authors:  Jessica R Kinsey; Stephen D Gilson; Joe Hauptman; Steve J Mehler; Lauren R May
Journal:  Can Vet J       Date:  2015-06       Impact factor: 1.008

4.  Evaluation of an actinomycin-D-containing combination chemotherapy protocol with extended maintenance therapy for canine lymphoma.

Authors:  Cecile T Siedlecki; Philip H Kass; Martin J Jakubiak; Gillian Dank; Jarred Lyons; Michael S Kent
Journal:  Can Vet J       Date:  2006-01       Impact factor: 1.008

5.  Evaluation of a side population of canine lymphoma cells using Hoechst 33342 dye.

Authors:  Myung-Chul Kim; Susan D'Costa; Steven Suter; Yongbaek Kim
Journal:  J Vet Sci       Date:  2013-06-30       Impact factor: 1.672

6.  Multicenter, randomized, double-blinded, placebo-controlled study of rabacfosadine in dogs with lymphoma.

Authors:  Kristen M Weishaar; Zachary M Wright; Mona P Rosenberg; Gerald S Post; Jennifer A McDaniel; Craig A Clifford; Brenda S Phillips; Philip J Bergman; Elissa K Randall; Anne C Avery; Douglas H Thamm; Abigail A Christman Hull; Cathy M Gust; Ann R Donoghue
Journal:  J Vet Intern Med       Date:  2021-12-24       Impact factor: 3.333
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.